News - Eisai

Filter

Current filters:

Eisai

Popular Filters

90 to 113 of 113 results

Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad

28-12-2011

Japanese drug major Eisai (TYO: 4523) says that it has re-submitted the New Drug Application (NDA) for…

Anti-viralsEisaiGilead SciencesNeurologicalperampanelPharmaceuticalQuadRegulation

Eisai in deal with Novartis to co-promote COPD drugs in Japan

21-11-2011

Japanese drugmaker Eisai (TYO: 4523) has entered into a Japan co-promotion agreement with the local subsidiary…

Asia-PacificEisaiLicensingMarkets & MarketingNovartisOnbrezPharmaceuticalRespiratory and Pulmonary

UK’s NICE rejects Eisai’s Halaven for advanced breast cancer

17-11-2011

In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Mixed half-year results from Astellas, Eisai and Santen

02-11-2011

Compared with some of its peers which reported first-half fiscal year 2011/12 (ended September 30) financial…

Astellas PharmaEisaiFinancialPharmaceuticalSanten Pharmaceuticals

Eisai wins patent extension in Japan for blockbuster Alzheimer’s drug Aricept

15-09-2011

Japanese drug major Eisai (TYO: 4523) says that the Supreme Court of Japan has turned down a petition…

AriceptAsia-PacificEisaiGenericsNeurologicalPatentsPharmaceutical

Eisai updates on epilepsy drugs Zonegran, Zebinix and perampanel at IEC

31-08-2011

Japanese drug major Eisai (TYO: 4523) presented new data at the International Epilepsy Congress taking…

BIALEisaieslicarbazepineNeurologicalperampanelPharmaceuticalResearchZebinixZonegran

Abbott and Eisai launch of PDER drug Lipacreon in Japan

31-08-2011

Following regulatory approval earlier this year (The Pharma Letter April 27), the Japanese subsidiary…

Abbott LaboratoriesAsia-PacificEisaiGastro-intestinalsLipacreonMarkets & MarketingPharmaceutical

Eisai sets up subsidiary in Mexico to expand Latin American presence

17-08-2011

Following in the path of other Japanese drug majors, Eisai (TYO: 4523), through its US unit, has established…

EisaiMarkets & MarketingPharmaceuticalSouth America

Arena and Eisai release data on obesity drug candidate lorcaserin to be used in CRL response

03-08-2011

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese partner Eisai (TYO: 4523) announced the completion…

Arena PharmaceuticalsEisailorcaserinMetabolicsPharmaceuticalResearch

Eisai epilepsy drug delayed by US FDA, but Zonegran use extension filing accepted in EU

01-08-2011

There was disappointment for Japanese drug major Eisai (TYO: 4523) last week when the US Food and Drug…

EisaiEuropeNeurologicalNorth AmericaperampanelPharmaceuticalRegulationZonegran

Daiichi Sankyo debuts Lixiana in Japan for VTE prevention after orthopedic surgery

20-07-2011

Building on its cardiovascular portfolio, Japanese drug major Daiichi Sankyo (TYO: 4568) has launched…

Asia-PacificCardio-vascularEisaiLixianaMarkets & MarketingPharmaceutical

Negative draft guidance from UK’s NICE for Eisai’s Halaven

20-07-2011

In yet another negative opinion for breast cancer use on the UK’s National Health Service, UK drugs…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Eisai gets Chinese rights for Orion’s Fareston and Eldepryl; FDA accepts Dacogen sNDA

14-07-2011

Japanese drug major Eisai (TYO: 4523) has entered into a comprehensive marketing agreement with Finland’s…

DacogenEisaiEldeprylFarestonOrion Pharma

Eisai to file Zonegran as first-line epilepsy therapy in Europe on good trial results

13-07-2011

Based on the positive results of a late-stage clinical trial, Japanese drug major Eisai’s (TYO:…

EisaiEuropeNeurologicalPharmaceuticalRegulationResearchZonegran

Pfizer Japan unveils positive top-line Ph III results for Lyrica in fibromyalgia

07-07-2011

The Japanese subsidiary of global drugs behemoth Pfizer (NYSE: PFE) has released top-line results from…

Asia-PacificEisaiLyricaNeurologicalPfizerPharmaceuticalResearch

Public Citizen says US FDA should immediately pull Eisai and Pfizer’s high-dose Aricept from market

19-05-2011

US consumer watchdog Public Citizen has called for higher doses of Aricept (donepezil), marketed by originator…

AriceptEisaiNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Eisai gets Swiss approval for Halaven

19-05-2011

Japanese drug major Eisai (TYO: 4532), says that its Halaven(eribulin) has been approved for use in…

EisaiEuropeHalavenOncologyPharmaceuticalRegulation

US FDA not ready to approve Eisai Aricept Patch; Lipacreon and Halaven OKed in Japan

27-04-2011

Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has issued a Complete…

AriceptAsia-PacificEisaiHalavenLipacreonNeurologicalNorth AmericaOncologyPfizerPharmaceuticalRegulation

90 to 113 of 113 results

Back to top